George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Watch this, screams remote/stand alone LOAC 'Real Time' solution and #SKIN way ahead on a solution, compared to this lab in Germany.
https://edition.cnn.com/videos/world/2020/05/29/germany-excrement-sewage-coronavirus-early-detection-pleitgen-pkg-intl-hnk-vpx.cnn
'The preparation of challenge trials should also be treated with similar Manhattan-Project-like urgency, given their potential value and the comparatively microscopic costs of preparation. Developing the challenge model and building needed biocontainment capacity would cost millions of dollars but might save tens of billions on unnecessary vaccine manufacturing alone.'
https://www.statnews.com/2020/05/28/challenge-trials-speed-development-covid-19-vaccine-start-planning-now/
Yet another article, still exposure of the need or demand if you like.
https://www.statnews.com/2020/05/28/wastewater-testing-gains-support-as-covid19-early-warning/
A point of correction on SP to Mcap. Don't forget that come 12th June or thereabouts, we should be registering 663,860,098 ordinary shares. This would mean a potential £400 Mcap, translates to an SP of circa 60p. So about 4x now and yet obviously sill a fantastic price if achieved.
Will ORPH not carry out the testing then for NHS Scotland, if a deal done ?
https://www.dailyrecord.co.uk/news/scottish-news/bosses-plea-over-fears-scotland-22076582
Fairview, not exactly encouraging atm
'The study authors at NYU Langone Health in New York said the Abbott test was so inaccurate that it was "unacceptable" for use with their patients.'
"The White House might have to call an audible and switch tests," said Dr. Peter Hotez, a professor at Baylor University School of Medicine in Houston. "Calling an audible" is a football term when the quarterback changes the play at the last minute.
https://www.google.com/amp/s/amp.cnn.com/cnn/2020/05/13/health/abbott-covid-test-misses-cases-health/index.html
I don't think the UK Government will now consider or use these.
https://amp.cnn.com/cnn/2020/05/13/health/abbott-covid-test-misses-cases-health/index.html
Just released
https://www.proactiveinvestors.co.uk/companies/amp/news/919594?__twitter_impression=true
https://amp.cnn.com/cnn/2020/05/13/us/coronavirus-human-challenge-study-invs/index.html
Rudey and andinio - thanks, certainly got some answers from that Quotient CEO Interview the rest will have to wait. Cheers.
Hope someone can answer my queries, as I was not clear on the situation from the Sharesoc Interview. CF seemed to say ORPH will buy the machine(s) and kit and then they will take control of all distribution, testing, results notification etc... Or at least that is the way I understood it.
So if right, my queries for which some of you may have ascertained off CF or elsewhere, would be appreciated;
* How many of these MosaiQ platform machines are we buying and how much are they ?
* Any idea how much each test kit will cost us and what likely charge ORPH will be charging on each request ?
* I may have missed it, but did CF have a figure in mind of how many tests they would be looking to do per day, once up and running ?
Apologies if I have misunderstood the structure of the partnership/operation and therefore would negate or adjust the type of questions I should ask :)
'Chief executive Franz Walt was managing director of the Singapore-based ROCHE Laboratory...'
'The US government’s medical research arm is preparing the ground for Covid-19 “human challenge trials” that would deliberately infect healthy volunteers with coronavirus, as part of efforts to accelerate work on the development of a vaccine.'
Francis Collins, director of National Institutes of Health, has asked the NIH vaccines working group to “write a perspective on the scientific and practical considerations for a Covid-19 human challenge model”.
https://amp.ft.com/content/0e7f1aff-9323-4d82-93ff-bbc5c20514d0
'Risk of COVID-19 transmission from wastewater higher than believed, study claims'
https://www.foxnews.com/science/risk-of-covid-19-transmission-from-waste-water-higher-than-believed-study-claims.amp
Gerard, thanks for the supplementary comments. Appreciated ??
Score - good spot, I must have scanned over that without too much thought at the time.
GG1111 - Just in case you are not aware, as you I think you only reference two events in your last but one post, there are actually 3 presentation/events lined up by ORPH in May;
11th May Sharesoc
14th May Shares Mag/AJ Bell
28th May Proactive (One2One)
Anyhow, to answer your question, looking at the source code for the Sharesoc/ORPH webinar of the 11th May, it looks like it was published/created on 2nd May. So only on Friday, hence perhaps why another poster 'Trek_Madone' perhaps came across bit and posted on it on the evening of that same day (as a brand new search find).
CF stated in one of his very recent Interviews, that (slightly paraphrased, but CAPITALS word for word).
"...their is Chinese pharmaceutical who had just started a Phase vaccine 2 trial with 500 people for Covid-19...and they are LOOKING FOR A HUMAN CHALLENGE STUDY...".
That company is 'CanSinio Biologics', Mcap circa HK$36 Billion. So one to watch out for results of phase 2, but at the same time if they indeed want to do a CHIM, will this indeed force others to seek to do the same, or potentially be left behind in their own race for vaccine development. ??
I pretty much agree with Shareseeker10. CF said in a couple of interviews post hvivo takeover and Covid-19 outbreak etc.. that he would be looking to sell the company 2-3 times the current Mcap. These comments made before Covid-19 really started a global pandemic shutdown, health crisis and economic shut down. Now political pressure will most certainly be pushing for virology, anti-viral and vaccine testing projects for anything deemed a threat to society and for fear of mutations as well. In other words ORPH services and facilities should be in big demand.
There still seems contentious feelings for CHIM to used for is Covid-19, as many an article is challenging it's use for ethical and safety reasons when so little is known of the SARS-COV-2 virus. I am not saying it will not be used, but hurdles I think to go through and no doubt being worked on. It could be as per CF's recent comments that they do some remote CHIM's for the Chinese, the US etc as not to sure in UK thinking for this virus only. No issue for CHIM use on more well known Viruses etc.. however and that will indeed be of growing interest also.
Certainly think that progression will very much be made, further contracts signed (as per pipeline) and perhaps like the last one of known value, for more than was initially sought. At the same time, new contacts being made and interest apparently growing for there services will only help affirm a takeover value of at least the top end of CF's 2- 3x Mcap, i.e. £100m.
If (LIKELY) 'Flu-V' FDA approval achieved soon, licensing out P3 progresses and the interest in 'AGS-v Plus' also gains momentum (CF seemed quite chipper on this also recently) etc.., then yes this will surely push any takeover valuation considerably above £100m, the question is by how much.
Each has there own thoughts on this of course and I respect that. One thing's for sure, I am happy to be involved and see it out. GLA.
Interesting and worth a read, Andrew Catchpole makes three seperate small comments within.
https://www.freethink.com/articles/coronavirus-vaccine-development
Two articles today, worth reading.
https://www.nature.com/articles/d41586-020-01179-x
https://www.aljazeera.com/amp/news/2020/04/coronavirus-hundreds-infected-vaccine-trials-200423093145968.html